As of 2025-09-16, the EV/EBITDA ratio of Karyopharm Therapeutics Inc (KPTI) is -3.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. KPTI's latest enterprise value is 272.03 mil USD. KPTI's TTM EBITDA according to its financial statements is -83.37 mil USD. Dividing these 2 quantities gives us the above KPTI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.1x - 11.3x | 8.4x |
| Forward P/E multiples | 14.8x - 19.1x | 19.0x |
| Fair Price | (167.43) - (134.16) | (156.85) |
| Upside | -2774.5% - -2243.1% | -2605.6% |
| Date | EV/EBITDA |
| 2025-09-10 | -3.26 |
| 2025-09-09 | -3.27 |
| 2025-09-08 | -3.26 |
| 2025-09-05 | -3.30 |
| 2025-09-04 | -3.31 |
| 2025-09-03 | -3.35 |
| 2025-09-02 | -3.32 |
| 2025-08-29 | -3.35 |
| 2025-08-28 | -3.41 |
| 2025-08-27 | -3.42 |
| 2025-08-26 | -3.39 |
| 2025-08-25 | -3.27 |
| 2025-08-22 | -3.27 |
| 2025-08-21 | -3.24 |
| 2025-08-20 | -3.29 |
| 2025-08-19 | -3.26 |
| 2025-08-18 | -3.19 |
| 2025-08-15 | -3.23 |
| 2025-08-14 | -3.10 |
| 2025-08-13 | -3.07 |
| 2025-08-12 | -3.03 |
| 2025-08-11 | -3.00 |
| 2025-08-08 | -3.02 |
| 2025-08-07 | -3.02 |
| 2025-08-06 | -3.03 |
| 2025-08-05 | -3.02 |
| 2025-08-04 | -3.03 |
| 2025-08-01 | -3.02 |
| 2025-07-31 | -3.01 |
| 2025-07-30 | -3.03 |
| 2025-07-29 | -3.04 |
| 2025-07-28 | -3.07 |
| 2025-07-25 | -3.06 |
| 2025-07-24 | -3.07 |
| 2025-07-23 | -3.12 |
| 2025-07-22 | -3.02 |
| 2025-07-21 | -3.03 |
| 2025-07-18 | -3.01 |
| 2025-07-17 | -3.04 |
| 2025-07-16 | -3.05 |
| 2025-07-15 | -3.05 |
| 2025-07-14 | -3.11 |
| 2025-07-11 | -3.09 |
| 2025-07-10 | -3.13 |
| 2025-07-09 | -3.11 |
| 2025-07-08 | -3.10 |
| 2025-07-07 | -3.05 |
| 2025-07-03 | -3.07 |
| 2025-07-02 | -3.09 |
| 2025-07-01 | -3.07 |